Company Description: Tundra Targeted Therapeutics develops bispecific antibodies to treat difficult cancers. The lead candidate targets leukemia and lymphoma by harnessing and activating a patient’s own T cells. Tundra’s novel antibody binds a validated tumor marker and is delivered with a pre-complexing process to enable efficacy at 1,000x lower dosing. We believe clinical trials, beginning in 2024, will demonstrate cancer remission and a safety profile that far exceeds today’s standard of care.